ALAR vs BCYC vs CGNT vs PEPG vs VRNS

For growth investors, Bicycle Therapeutics plc (BCYC) is the stronger pick with 105.

8% revenue growth year-over-year, versus 11. 9% for Cognyte Software Ltd. (CGNT). Alarum Technologies Ltd. (ALAR) offers the better valuation at 9. 4x trailing P/E, making it the more compelling value choice. Analysts rate Bicycle Therapeutics plc (BCYC) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Cognyte Software Ltd.

is actually cheaper at 46. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Alarum Technologies Ltd.

(ALAR) delivered a total return of -36. 6%, compared to -86. 1% for PepGen Inc. (PEPG). Over 10 years, the gap is even starker: VRNS returned +317. 5% versus ALAR's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), PepGen Inc.

(PEPG) is the lower-risk stock at 0. 17β versus Alarum Technologies Ltd. 's 2. 01β — meaning ALAR is approximately 1062% more volatile than PEPG relative to the S&P 500. On balance sheet safety, Bicycle Therapeutics plc (BCYC) carries a lower debt/equity ratio of 3% versus 96% for Varonis Systems, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bicycle Therapeutics plc (BCYC) is pulling ahead at 105.

8% versus 11. 9% for Cognyte Software Ltd. (CGNT). On earnings-per-share growth, the picture is similar: Alarum Technologies Ltd. grew EPS 160. 7% year-over-year, compared to -31. 4% for Varonis Systems, Inc.. Over a 3-year CAGR, BCYC leads at 71. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alarum Technologies Ltd.

(ALAR) is the more profitable company, earning 18. 2% net margin versus -301. 7% for Bicycle Therapeutics plc — meaning it keeps 18. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALAR leads at 21. 1% versus -341. 3% for BCYC. At the gross margin level — before operating expenses — BCYC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Cognyte Software Ltd.

(CGNT) trades at 46. 9x forward P/E versus 242. 2x for Varonis Systems, Inc. — 195. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PEPG: 291. 1% to $7. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, PepGen Inc.

(PEPG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 17)). Alarum Technologies Ltd. (ALAR) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PEPG: -86. 1%, ALAR: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ALAR (Technology) and BCYC (Healthcare) and CGNT (Technology) and PEPG (Healthcare) and VRNS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ALAR is a small-cap high-growth stock; BCYC is a small-cap high-growth stock; CGNT is a small-cap quality compounder stock; PEPG is a small-cap quality compounder stock; VRNS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.